These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 8577629)

  • 1. Overview of cost-consequence modeling in outcomes research.
    Stergachis A
    Pharmacotherapy; 1995; 15(5 Pt 2):40S-42S. PubMed ID: 8577629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cost-consequence models in managed care.
    Blissenbach HF
    Pharmacotherapy; 1995; 15(5 Pt 2):59S-61S. PubMed ID: 8577632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research.
    Kozma CM; Reeder CE; Schulz RM
    Clin Ther; 1993; 15(6):1121-32; discussion 1120. PubMed ID: 8111809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of cost-effectiveness research.
    Ganiats TG; Schneiderman LJ
    J Fam Pract; 1988 Jul; 27(1):77-84. PubMed ID: 3134508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes research and modeling therapeutic interventions for economic evaluations.
    Langley PC
    Clin Ther; 1994; 16(3):538-52. PubMed ID: 7923319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive model of clinical decision making.
    Corliss DA
    J Am Optom Assoc; 1995 Jun; 66(6):362-71. PubMed ID: 7673596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Collection and elaboration of the economic information necessary for calculating the costs of therapeutic decisions].
    Viens-Bitker C; Leclercq B
    Arch Mal Coeur Vaiss; 1989 Oct; 82 Spec No 3():49-53. PubMed ID: 2512888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the cost of health care-associated infections: mind your p's and q's.
    Graves N; Harbarth S; Beyersmann J; Barnett A; Halton K; Cooper B
    Clin Infect Dis; 2010 Apr; 50(7):1017-21. PubMed ID: 20178419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory care warrants studies for cost-effectiveness.
    Burton GG; Gee GN; Hodgkin JE; Dunham JL
    Hospitals; 1975 Nov; 49(22):61, 64-5, 71. PubMed ID: 810401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations.
    Trikalinos TA; Siebert U; Lau J
    Med Decis Making; 2009; 29(5):E22-9. PubMed ID: 19734441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.